Thomas Berg
Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome
Efe C, Nilsson E, Heurgué-Berlot A, Demir N, Semela D, Kiyici M, Schiano T, Montano-Loza A, Berg T, Ozaslan E, Yoshida E, Bonder A, Marschall H, Beretta-Piccoli B, Önnerhag K, Rorsman F, Torgutalp M, Henriksson I, Alalkim F, Lytvyak E, Trivedi H, Eren F, Fischer J, Chayanupatkul M, Coppo C, Purnak T, Muratori L, Werner M, Muratori P, Wahlin S. Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome. J Gastroenterol Hepatol 2020
13.08.2020Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome
13.08.2020J Gastroenterol Hepatol 2020
Efe Cumali, Nilsson Emma, Heurgué-Berlot Alexandra, Demir Nurhan, Semela David, Kiyici Murat, Schiano Thomas D, Montano-Loza Aldo J, Berg Thomas, Ozaslan Ersan, Yoshida Eric M, Bonder Alan, Marschall Hanns-Ulrich, Beretta-Piccoli Benedetta Terziroli, Önnerhag Kristina, Rorsman Fredrik, Torgutalp Murat, Henriksson Ida, Alalkim Fatema, Lytvyak Ellina, Trivedi Hirsh, Eren Fatih, Fischer Janett, Chayanupatkul Maneerat, Coppo Claudia, Purnak Tugrul, Muratori Luigi, Werner Mårten, Muratori Paolo, Wahlin Staffan
Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections
Dietz J, Backhus J, Zizer E, Boettler T, Neumann-Haefelin C, Semela D, Stauber R, Berg T, Berg C, Zeuzem S, Vermehren J, Sarrazin C, Buggisch P, Matschenz K, Spengler U, Mullhaupt B, Schulze Zur Wiesch J, Piecha F, Mauss S, Seegers B, Hinrichsen H, Antoni C, Wietzke-Braun P, Peiffer K, Berger A, European HCV Resistance Study Group. Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections. Clin Gastroenterol Hepatol 2019
06.11.2019Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections
06.11.2019Clin Gastroenterol Hepatol 2019
Dietz Julia, Backhus Johanna, Zizer Eugen, Boettler Tobias, Neumann-Haefelin Christoph, Semela David, Stauber Rudolf, Berg Thomas, Berg Christoph, Zeuzem Stefan, Vermehren Johannes, Sarrazin Christoph, Buggisch Peter, Matschenz Katrin, Spengler Ulrich, Mullhaupt Beat, Schulze Zur Wiesch Julian, Piecha Felix, Mauss Stefan, Seegers Barbara, Hinrichsen Holger, Antoni Christoph, Wietzke-Braun Perdita, Peiffer Kai-Henrik, Berger Annemarie, European HCV Resistance Study Group
Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis
Efe C, Günşar F, Nilsson E, Heurgué-Berlot A, Güzelbulut F, Demir N, Gönen C, Semela D, Aladağ M, Kiyici M, Schiano T, Montano-Loza A, Berg T, Ozaslan E, Yoshida E, Bonder A, Marschall H, Önnerhag K, Rorsman F, Muratori P, Taşçilar K, Henriksson I, Lytvyak E, Alalkim F, Trivedi H, Eren F, Eliasson J, Beretta-Piccoli B, Fischer J, Calişkan A, Chayanupatkul M, Coppo C, Ytting H, Purnak T, Muratori L, Werner M, Wahlin S. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis. Am J Gastroenterol 2019; 114:1101-1108.
01.07.2019Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis
01.07.2019Am J Gastroenterol 2019; 114:1101-1108
Efe Cumali, Günşar Fulya, Nilsson Emma, Heurgué-Berlot Alexandra, Güzelbulut Fatih, Demir Nurhan, Gönen Can, Semela David, Aladağ Murat, Kiyici Murat, Schiano Thomas D, Montano-Loza Aldo J, Berg Thomas, Ozaslan Ersan, Yoshida Eric M, Bonder Alan, Marschall Hanns-Ulrich, Önnerhag Kristina, Rorsman Fredrik, Muratori Paolo, Taşçilar Koray, Henriksson Ida, Lytvyak Ellina, Alalkim Fatema, Trivedi Hirsh, Eren Fatih, Eliasson Johanna, Beretta-Piccoli Benedetta Terziroli, Fischer Janett, Calişkan Ali Riza, Chayanupatkul Maneerat, Coppo Claudia, Ytting Henriette, Purnak Tugrul, Muratori Luigi, Werner Mårten, Wahlin Staffan
Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study
Kolly P, Waidmann O, Vermehren J, Moreno C, Vögeli I, Berg T, Semela D, Zeuzem S, Dufour J. Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study. J Hepatol 2017; 67:876-878.
19.07.2017Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study
19.07.2017J Hepatol 2017; 67:876-878
Kolly Philippe, Waidmann Oliver, Vermehren Johannes, Moreno Christophe, Vögeli Isabelle, Berg Thomas, Semela David, Zeuzem Stefan, Dufour Jean-François
A systematic review and meta-analysis of HCV clearance
Gauthiez E, Moradpour D, Mullhaupt B, Negro F, Semela D, Semmo N, Villard J, Bibert S, Bochud P, Malinverni R, Heim M, Habfast-Robertson I, Rüeger S, Kutalik Z, Aubert V, Berg T, Cerny A, Gorgievski M, George J, Swiss Hepatitis C Cohort Study. A systematic review and meta-analysis of HCV clearance. Liver Int 2017; 37:1431-1445.
30.03.2017A systematic review and meta-analysis of HCV clearance
30.03.2017Liver Int 2017; 37:1431-1445
Gauthiez Emeline, Moradpour Darius, Mullhaupt Beat, Negro Francesco, Semela David, Semmo Nasser, Villard Jean, Bibert Stéphanie, Bochud Pierre-Yves, Malinverni Raffaele, Heim Markus H, Habfast-Robertson Ines, Rüeger Sina, Kutalik Zoltán, Aubert Vincent, Berg Thomas, Cerny Andreas, Gorgievski Meri, George Jacob, Swiss Hepatitis C Cohort Study
A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance
Wang H, Pichulik T, Mullhaupt B, Semela D, Dufour J, Bochud P, Bowie A, Kalinke U, Berg T, Weber A, Wiese M, Löffler M, El Maadidi S, Fischer J, Grabski E, Dickhöfer S, Klimosch S, Flannery S, Filomena A, Wolz O, Schneiderhan-Marra N, East-German and Swiss Hepatitis C Virus Study Groups. A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance. Hepatology 2015; 62:1375-87.
28.09.2015A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance
28.09.2015Hepatology 2015; 62:1375-87
Wang Hui, Pichulik Tica, Mullhaupt Beat, Semela David, Dufour Jean-François, Bochud Pierre-Yves, Bowie Andrew G, Kalinke Ulrich, Berg Thomas, Weber Alexander N R, Wiese Manfred, Löffler Markus W, El Maadidi Souhayla, Fischer Janett, Grabski Elena, Dickhöfer Sabine, Klimosch Sascha, Flannery Sinead M, Filomena Angela, Wolz Olaf-Oliver, Schneiderhan-Marra Nicole, East-German and Swiss Hepatitis C Virus Study Groups
Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development
Lange C, Negro F, Semela D, Kutalik Z, Müller T, Spengler U, Berg T, Chayama K, Moradpour D, Bochud P, Hiroshima Liver Study Group, Mullhaupt B, Malinverni R, Heim M, Miki D, Ochi H, Nischalke H, Bojunga J, Bibert S, Morikawa K, Gouttenoire J, Cerny A, Dufour J, Gorgievski-Hrisoho M, Swiss Hepatitis C Cohort Study Group. Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development. PloS one 2013; 8:e64053.
29.05.2013Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development
29.05.2013PloS one 2013; 8:e64053
Lange Christian M, Negro Francesco, Semela David, Kutalik Zoltán, Müller Tobias, Spengler Ulrich, Berg Thomas, Chayama Kazuaki, Moradpour Darius, Bochud Pierre-Yves, Hiroshima Liver Study Group, Mullhaupt Beat, Malinverni Raffaele, Heim Markus H, Miki Daiki, Ochi Hidenori, Nischalke Hans-Dieter, Bojunga Jörg, Bibert Stéphanie, Morikawa Kenichi, Gouttenoire Jérôme, Cerny Andreas, Dufour Jean-François, Gorgievski-Hrisoho Meri, Swiss Hepatitis C Cohort Study Group
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study
Rauch A, Hirschel B, Malinverni R, Moradpour D, Mullhaupt B, Witteck A, Beckmann J, Berg T, Bergmann S, Negro F, Telenti A, Bochud P, Swiss Hepatitis C Cohort Study, Heim M, Günthard H, Furrer H, Kutalik Z, Descombes P, Cai T, di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour J, Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138:1338-45, 1345.e1-7.
11.01.2010Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study
11.01.2010Gastroenterology 2010; 138:1338-45, 1345.e1-7
Rauch Andri, Hirschel Bernard, Malinverni Raffaele, Moradpour Darius, Mullhaupt Beat, Witteck Andrea, Beckmann Jacques S, Berg Thomas, Bergmann Sven, Negro Francesco, Telenti Amalio, Bochud Pierre-Yves, Swiss Hepatitis C Cohort Study, Heim Markus, Günthard Huldrych F, Furrer Hansjakob, Kutalik Zoltán, Descombes Patrick, Cai Tao, di Iulio Julia, Mueller Tobias, Bochud Murielle, Battegay Manuel, Bernasconi Enos, Borovicka Jan, Colombo Sara, Cerny Andreas, Dufour Jean-François, Swiss HIV Cohort Study
Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients
Berg T, Sarrazin C, Neumann K, Zankel M, Balk H, Buggisch P, Spengler U, Gerlach T, Hinrichsen H, Rasenack J, Möller B, Klinker H, Teuber G, Weich V, Zeuzem S. Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology (Baltimore, Md.) 2009; 50:369-77.
01.08.2009Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients
01.08.2009Hepatology (Baltimore, Md.) 2009; 50:369-77
Berg Thomas, Sarrazin Christoph, Neumann Konrad, Zankel Myrga, Balk Heike, Buggisch Peter, Spengler Ulrich, Gerlach Tilman, Hinrichsen Holger, Rasenack Jens, Möller Bernd, Klinker Hartwig, Teuber Gerlinde, Weich Viola, Zeuzem Stefan
Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial
Kronenberger B, Hopf U, Pape G, Wursthorn K, Nasser S, Goeser T, Spengler U, Buggisch P, Gerlach T, Hinrichsen H, Herrmann E, Berg T, Zeuzem S. Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial. European journal of gastroenterology & hepatology 2007; 19:639-46.
01.08.2007Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial
01.08.2007European journal of gastroenterology & hepatology 2007; 19:639-46
Kronenberger Bernd, Hopf Uwe, Pape Gerd R, Wursthorn Karsten, Nasser Samer, Goeser Tobias, Spengler Ulrich, Buggisch Peter, Gerlach Tilman, Hinrichsen Holger, Herrmann Eva, Berg Thomas, Zeuzem Stefan
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin
Berg T, Alshuth U, Martus P, Spengler U, Klinker H, Kallinowski B, Schmidt W, Pape G, Rasenack J, Goeser T, Buggisch P, Gerlach T, Heintges T, Sarrazin C, Nasser S, von Wagner M, Zeuzem S. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130:1086-97.
01.04.2006Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin
01.04.2006Gastroenterology 2006; 130:1086-97
Berg Thomas, Alshuth Ulrich, Martus Peter, Spengler Ulrich, Klinker Hartwig, Kallinowski Birgit, Schmidt Wolfgang E, Pape Gerd R, Rasenack Jens, Goeser Tobias, Buggisch Peter, Gerlach Tilman, Heintges Tobias, Sarrazin Christoph, Nasser Samer, von Wagner Michael, Zeuzem Stefan
Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C
von Wagner M, Herrmann E, Häussinger D, Bernsmeier C, Bergk A, Heintges T, Rasenack J, Hinrichsen H, Berg T, Huber M, Zeuzem S. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129:522-7.
01.08.2005Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C
01.08.2005Gastroenterology 2005; 129:522-7
von Wagner Michael, Herrmann Eva, Häussinger Dieter, Bernsmeier Christine, Bergk Alexandra, Heintges Tobias, Rasenack Jens, Hinrichsen Holger, Berg Thomas, Huber Miriam, Zeuzem Stefan
Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C?
Berg T, Sarrazin C, Hinrichsen H, Buggisch P, Gerlach T, Zachoval R, Zeuzem S. Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C?. Hepatology (Baltimore, Md.) 2004; 39:1456-7; author reply 1457-8.
01.05.2004Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C?
01.05.2004Hepatology (Baltimore, Md.) 2004; 39:1456-7; author reply 1457-8
Berg Thomas, Sarrazin Christoph, Hinrichsen Holger, Buggisch Peter, Gerlach Tilman, Zachoval Reinhart, Zeuzem Stefan
Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial
Berg T, Hopf U, Pape G, Wursthorn K, Nasser S, Goeser T, Spengler U, Herrmann E, Buggisch P, Gerlach T, Hinrichsen H, Kronenberger B, Zeuzem S. Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial. Hepatology (Baltimore, Md.) 2003; 37:1359-67.
01.06.2003Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial
01.06.2003Hepatology (Baltimore, Md.) 2003; 37:1359-67
Berg Thomas, Hopf Uwe, Pape Gerd R, Wursthorn Karsten, Nasser Samer, Goeser Tobias, Spengler Ulrich, Herrmann Eva, Buggisch Peter, Gerlach Tilman, Hinrichsen Holger, Kronenberger Bernd, Zeuzem Stefan
Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy
Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, Wiedenmann B, Hopf U, Zeuzem S. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology (Baltimore, Md.) 2003; 37:600-9.
01.03.2003Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy
01.03.2003Hepatology (Baltimore, Md.) 2003; 37:600-9
Berg Thomas, Sarrazin Christoph, Herrmann Eva, Hinrichsen Holger, Gerlach Tilman, Zachoval Reinhart, Wiedenmann Bertram, Hopf Uwe, Zeuzem Stefan
Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia.
Burchert A, Wölfl S, Schmidt M, Brendel C, Denecke B, Cai D, Odyvanova L, Lahaye T, Müller M, Berg T, Gschaidmeier H, Wittig B, Hehlmann R, Hochhaus A, Neubauer A. Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 2002; 101:259-64.
28.06.2002Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia.
28.06.2002Blood 2002; 101:259-64
Burchert Andreas, Wölfl Stefan, Schmidt Manuel, Brendel Cornelia, Denecke Barbara, Cai Dali, Odyvanova Larissa, Lahaye Tanja, Müller Martin, Berg Thomas, Gschaidmeier Harald, Wittig Burghardt, Hehlmann Rüdiger, Hochhaus Andreas, Neubauer Andreas